MedTrace Logo

Hemodynamic Stability in Septic Shock Patients Undergoing Continuous Renal Replacement Therapy With oXiris Membrane

NCT05575024 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 98

Last updated 2025-05-15

No results posted yet for this study

Summary

The new adsorbing membrane for continuous renal replacement therapy (CRRT), oXiris, can reduce plasma cytokines and endotoxins in septic shock patients with severe acute kidney injury, compared with standard membranes. However, its hemodynamic stability or benefits have not been thoroughly evaluated although this is reasonable.

Conditions

  • Acute Kidney Injury Due to Sepsis

Interventions

DEVICE

oXiris membrane

Perform continuous renal replacement therapy with oXiris membrane

DEVICE

Polysulfone membrane

Perform continuous renal replacement therapy with polysulfone membrane

Sponsors & Collaborators

  • Seoul National University Hospital

    lead OTHER

Principal Investigators

  • Seung Seok Han, M.D. · Seoul National University Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-01-01
Primary Completion
2026-06-30
Completion
2026-12-31
FDA Device
Yes

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05575024 on ClinicalTrials.gov